3 New Strong Buy Ratings from Top-Rated Analysts: 05/12/2026

Don’t miss these Strong Buy ratings, hot off the presses from our most popular screener: 

• Jazz Pharmaceuticals PLC (JAZZ) — #1 biotech stock with elite analyst conviction.
• Scorpio Tankers Inc (STNG) — Unanimous Strong Buy with 69% profit margins.
• Marathon Petroleum Corp (MPC) — Refining giant riding geopolitical tailwinds to 30%+ upside.

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

A note from our sponsors...

Here's the Best Day to Buy Nvidia

Did you know Nvidia has a 93% history of soaring, beginning on one particular day every single spring?

We call this the "Green Day phenomenon." It works on 5,000 stocks.

For example, Amazon has a 100% history of soaring beginning on one particular day every single year.

Click here to see the green days for 5 major stocks today.

1. Scorpio Tankers Inc (NYSE: STNG)

With a fleet of 131 refined petroleum product tankers and a jaw-dropping 69.1% profit margin, Scorpio Tankers is in a league of its own. Recent convertible note offerings paired with aggressive stock repurchases show management is doubling down on favorable tanker market dynamics — and investors are taking notice.

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $84.41 — get current quote

Max 1-year forecast: $100.00

Why we're watching:

• Analyst support: 5 analysts cover STNG. Right now, it boasts 4 Strong Buy ratings and 1 Buy rating, representing unanimous bullish sentiment on the tanker operator's prospects. See the ratings
• For example, Bank of America's Ken Hoexter (a top 10% rated analyst) recently upgraded STNG to Strong Buy with a $100 price target, signaling increasing confidence in the company's trajectory.
• Industry ranking context: STNG is currently the #2 highest-rated stock in the Oil & Gas Midstream industry, which carries a C rating.
• Zen Rating highlights: STNG earns an overall A or Strong Buy rating, firmly placing it in the top 5% of stocks we track based on fundamentals. The Component Grades that shape the overall rating reveal specific strengths: STNG combines exceptional Value (A) and Financials (A) grades with solid Momentum (B) and Sentiment (B), reflecting both operational excellence and market recognition. (See all 7 Zen Component Grades here)

2. Marathon Petroleum Corp (NYSE: MPC)

This energy heavyweight is firing on all cylinders, with refineries spanning the Gulf Coast, Mid-Continent, and West Coast capitalizing on elevated refining margins driven by Middle East tensions. MPC's integrated operations and strategic positioning have turned market volatility into a goldmine — all while delivering robust shareholder returns.

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $244.87 — get current quote

Max 1-year forecast: $335.00

Why we're watching:

• Analyst support: 12 analysts cover MPC with 6 Strong Buy ratings, 3 Buy ratings, and 3 Hold ratings, with a Strong Buy consensus. See the ratings
• For example, Raymond James' Justin Jenkins (top 1%), who maintains a Buy rating, noted in his preview that although Q1 margins spiked due to the Middle East crisis, forward strip margins indicate significantly greater earnings potential in Q2 and beyond, with enhanced refining margins expected to persist after the conflict ends.
• TD Cowen analyst Jason Gabelman (top 18%) maintains the highest price target at $320, representing over 30% upside potential from current levels.
• Industry ranking context: MPC is currently the #3 highest-rated stock in the Oil & Gas Refining & Marketing industry, which has an excellent A rating, demonstrating strong performance in a favorable sector environment.
• Zen Rating highlights: MPC earns an overall A or Strong Buy rating. Stocks with this elite rating have historically generated 32.52% in annual returns. (See all 7 Zen Component Grades here)

3. Jazz Pharmaceuticals (NASDAQ: JAZZ)

This leading biopharmaceutical powerhouse just delivered a Q1 earnings beat and scored FDA priority review acceptance for Ziihera — fueling its aggressive pivot into high-growth oncology markets while staying dominant in rare diseases. The neurological and psychiatric treatment specialist is making bold moves that have Wall Street paying close attention.

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $225.79 — get current quote

Max 1-year forecast: $275.00

Why we're watching:

• Analyst support: 12 analysts cover JAZZ with 7 Strong Buy ratings, 4 Buy ratings, and only 1 Hold, reflecting strong conviction in the company's growth trajectory. See the ratings
• Truist Securities' Joon Lee (a top 2% rated analyst) maintained a Strong Buy rating with a $230 price target, citing strong pipeline progress and robust growth strategy following the recent earnings report.
• Barclays researcher Etzer Darout (top 2%) emphasized Jazz's competitive edge in niche markets, noting that the company is well-positioned against competitors with anticipated regulatory approvals for pipeline drugs serving as near-term catalysts.
• Needham's Ami Fadia (top 1%) and RBC Capital's Leonid Timashev (top 7%) both highlight the company's potential expansion into underserved rare disease markets, with continued success expected to accelerate revenue growth.
• Industry ranking context: JAZZ is currently the #1 highest-rated stock in the Biotech industry, despite the industry receiving an F rating overall, demonstrating the company's exceptional positioning in a challenging sector.
• Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr. JAZZ is part of this elite tier of stocks. 
• Component Grades: The company earns A grades for both Value and Growth, with solid B grades in Financials and Momentum, indicating strong fundamentals and attractive valuation despite recent price appreciation. (See all 7 Zen Component Grades here)

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.